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Abstract
Background: By providing information on the relative merits and potential harms of the options
available and a framework to clarify preferences, decision aids can improve knowledge and realistic
expectations and decrease decisional conflict in individuals facing decisions between alternative
forms of action. Decision-making about prenatal testing for fetal abnormalities is often confusing
and difficult for women and the effectiveness of decision aids in this field has not been established.
This study aims to test whether a decision aid for prenatal testing of fetal abnormalities, when
compared to a pamphlet, improves women's informed decision-making and decreases decisional
conflict.
Methods/design: A cluster designed randomised controlled trial is being conducted in Victoria,
Australia. Fifty General Practitioners (GPs) have been randomised to one of two arms: providing
women with either a decision aid or a pamphlet. The two primary outcomes will be measured by
comparing the difference in percentages of women identified as making an informed choice and the
difference in mean decisional conflict scores between the two groups. Data will be collected from
women using questionnaires at 14 weeks and 24 weeks gestation.
The sample size of 159 women in both arms of the trial has been calculated to detect a difference
of 18% (50 to 68%) in informed choice between the two groups. The required numbers have been
adjusted to accommodate the cluster design, miscarriage and participant lost – to – follow up.
Baseline characteristics of women will be summarised for both arms of the trial. Similarly,
characteristics of GPs will be compared between arms.
Differences in the primary outcomes will be analysed using 'intention-to-treat' principles.
Appropriate regression techniques will adjust for the effects of clustering and include covariates to
adjust for the stratifying variable and major potential confounding factors.
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BMC Public Health 2006, 6:96 http://www.biomedcentral.com/1471-2458/6/96Discussion: The findings from this trial will make a significant contribution to improving women's
experience of prenatal testing and will have application to a variety of maternity care settings. The
evaluation of a tailored decision aid will also have implications for pregnancy care providers by
identifying whether or not such a resource will support their role in providing prenatal testing
information.
Background
Peak obstetric bodies [1-3] recommend that all pregnant
women, regardless of age, are provided with information
on prenatal screening tests for fetal abnormality. Women
often find this information difficult to understand and
studies have demonstrated low levels of knowledge [4-7].
Health professionals are an important source of informa-
tion for women, yet studies have demonstrated they too
can also experience difficulty in understanding the inher-
ent complexities related to screening tests [8-10]. Not sur-
prisingly, studies have consistently demonstrated a need
to improve women's capacity to make an informed deci-
sion regarding prenatal screening tests and the need for
women to have a more active role in decision-making. At
a minimum, women need to understand the condition(s)
for which the testing is being offered, the characteristics of
the test and the implications of testing [11].
Decision aids are resources that are designed to assist indi-
viduals to make specific and deliberate choices from avail-
able options by providing information on the options and
outcomes relevant to the individual's health status [12].
They have been found to improve individuals' decision-
making and outcomes in a variety of health related areas
[13] and have been established as effective in: improving
knowledge and realistic expectations of benefits and risks
of options, increasing participation in decision-making
and reducing decisional conflict without affecting levels
of anxiety or satisfaction. Despite promising results
among women of advanced maternal age using a decision
aid for prenatal diagnostic testing [14], the role of deci-
sion aids for women of all ages considering prenatal
screening tests has not been established.
We are undertaking a cluster randomised controlled trial
to test whether a decision aid for prenatal testing of fetal
abnormalities, when compared to a pamphlet, improves
women's informed decision-making [11] and decreases
their decisional conflict [15]. The trial, called ADEPT (A
DEcision Aid for Prenatal Testing of fetal abnormalities),
is being conducted in the primary health care setting, as
GPs are often the first health professional a woman con-
sults early in pregnancy. Consequently, this setting allows
for provision of the allocated information at a gestation
when women have the best chance to consider first and
second trimester testing options.
Methods/design
Design of the intervention
The decision aid for prenatal testing of fetal abnormalities
has been developed using the three steps of the Ottawa
Decision Support framework: identifying needs, provid-
ing decision support and evaluating decision support
[16].
The need for a decision aid was identified following a lit-
erature search and by conducting focus groups with the
target groups relevant to the study: five focus groups with
women and four with GPs were conducted in metropoli-
tan and regional Victoria, Australia. The key finding from
the GP focus groups was the difficulty GPs experienced in
making screening test information appropriate, relevant
and understandable to the individual women. In particu-
lar, explaining epidemiological concepts was identified as
challenging. GPs experienced significant time pressures in
the first consultation in pregnancy and strongly supported
the development of a tailored resource. The women's
focus groups revealed low level of prenatal screening
knowledge and diversity in the amount of information
women wanted. To accommodate this a flexible paper-
based format was drafted, incorporating the use of sum-
mary tables and dot points, as well as more detailed infor-
mation and a resource list. Consistently women identified
difficulty with statistical and numeric expressions and this
influenced the use of graphs and diagrams throughout the
decision aid. Draft formats of the decision aid were
piloted with women who were attending a tertiary prena-
tal clinic in early pregnancy.
The resultant decision aid is a 24-page information book-
let and a risk report. The booklet contains information on
why testing is offered, the range of chromosomal and
physical abnormalities for which tests may be offered, the
different types of tests available and the possible out-
comes of testing. Also, within the booklet are scenarios of
women's decision-making about testing, a list of other
resources available and a worksheet to assist women in
weighing up the benefits and risks of different options. A
risk report sheet detailing an individualised risk estima-
tion for having a pregnancy affected by Down syndrome
is generated, based on an algorithm involving the
woman's age and gestation [17,18]. The individual risk
estimate given to women was obtained through use of a
paper-based chart or a CD-ROM, and the GPs were givenPage 2 of 8
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The decision aid is being compared to a pamphlet devel-
oped by Genetic Health Services Victoria (GHSV). The
pamphlet is currently available free of charge within Vic-
toria. It is in the form of a fold out A3 paper size and con-
tains information on maternal age related risk, screening
and diagnostic tests, a table summarising the tests availa-
ble and what conditions they detect.
Ethics
Royal Australian College of General Practitioners has
granted ethics approval to conduct this trial (NREEC 03–
16). The trial complies with the principles of the Helsinki
Declaration [19]. A plain language statement is provided
to all women (see Additional file 1) and GPs in the study
and a signed consent form is obtained from all partici-
pants at the time of recruitment.
Setting for the trial
The ADEPT study is being conducted in the primary
health care setting of Victoria, one of the south-eastern
states of Australia, where approximately 62,000 women
give birth each year [20]. All women in Victoria booked to
give birth at a publicly funded maternity setting have
access to a second trimester maternal serum screening test,
free of charge. Within this public system, women identi-
fied as being at 'increased risk' for fetal abnormality on the
basis of their age (37 years or older) or screening test
result, have access to diagnostic testing that is fully
funded. Outside these criteria women incur out-of-pocket
expenses for most other screening or diagnostic tests,
although some costs are covered by a federally funded
rebate. All serum samples are sent to a centralised labora-
tory at GHSV for testing.
In Victoria, the provision of information on prenatal test-
ing options is not uniform. Some women receive informa-
tion that is verbal and/or written, while others receive no
information at all. The pamphlet produced by the GHSV
is one of a vast array of written information used through-
out the state. While the exact rate of uptake of screening
tests in the state is not known, it is estimated that approx-
imately 60% of pregnant women have some form of
screening test [21] and utilisation is increasing. An abnor-
mal screening test result was the indication for 44% of
diagnostic tests in 2004, compared to 41% for maternal
age alone [22].
Cluster design
Cluster randomisation has been chosen to avoid contam-
ination of the intervention to the control group, which
would dilute the difference between the groups thus
reducing the power of the study. It has been proposed that
the use of cluster randomisation can be justified when the
risk of contamination between groups is estimated to be
greater than 30% [23]. This level of contamination could
reasonably occur in the ADEPT study at the level of the
GP, or by women in the intervention group sharing the
decision aid with women in the control group within a
variety of maternity care environments, as well as through
social settings. It is also possible that the paper-based deci-
sion aid could be copied and circulated to women in the
control arm of the trial.
GPs were randomised either to the intervention arm, pro-
viding women with the decision aid, or in the control
arm, providing women with the GHSV pamphlet. The
individual GP was used as the unit of randomisation. It
was envisaged that the cluster design would have the
added advantage of assisting participating GPs to adhere
to the trial protocol [24], as they would be providing the
same resource to all women they recruited. Data are cur-
rently being collected from questionnaires completed by
women.
Sample size
The required sample size has been adjusted for the clus-
tered design and has been based on using a two-sided test
at a 0.05 level of significance and 80% power to detect a
difference of 18% (50 – 68%) in the rate of informed
choice between women in the intervention and control
groups. The anticipated difference in outcome measure
was based on a study assessing women's knowledge of
prenatal tests to detect Down Syndrome [4] and it was
judged that smaller effects would not be of public health
significance.
Using an intraclass correlation coefficient (ICC) of 0.05
and with 25 GPs in each arm of the trial, the design effect
was calculated as 1.25. ICC within the Australian primary
health context are seldom published [25], so we estimated
an ICC for our sample based on an unpublished survey of
50 currently pregnant women sampled consecutively in
30 GP practices in Victoria by one of the study's investiga-
tors (JG). This adjustment resulted in a sample estimate of
159 women per arm of the trial. The sample size was fur-
ther adjusted to allow for 35% attrition rate due to miscar-
riage in the first trimester [26] and non- return of the first
questionnaire [27]. The required recruitment sample was
estimated at 245 women per arm of the trial in order to
provide a total of 318 respondents for analysis.
Enrolling GPs in the ADEPT study
Geographical areas were purposively targeted to achieve a
geographical spread in the location of general practices
throughout the metropolitan area. As approximately one-
fifth of Victorian births occur in rural areas [28], these
areas were also targeted to ensure non-metropolitan rep-Page 3 of 8
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basis of the number of first trimester samples sent to the
centralised laboratory at GHSV in 2004.
Individual letters inviting expressions of interest in the
study were sent to GPs (see Additional file 2). The contact
details of GPs were obtained from professional organisa-
tions, public telephone listings and in-house databases of
GPs interested in prenatal testing. Other strategies also
involved advertising the ADEPT study through profes-
sional organisations and medical media.
Selection of GPs
Eligibility criteria required that the GP estimated that s/he
consults with at least 30 women in early pregnancy within
a twelve-month period. Participation was limited to one
GP per practice to minimise the potential for contamina-
tion previously described. In addition, it was hoped that
this restriction would also increase the generalisability of
the findings, as GPs who practise together are more likely
to share other characteristics such as practice style and atti-
tudes. The 50 GPs participating in the study were asked to
each recruit ten women to the trial.
Randomisation of GPs
A person independent to the study has conducted all ran-
domisation procedures for this study. Initially, the names
of the 63 GPs expressing interest in the study were ran-
domly sorted. GPs were contacted by phone using the
numerical order of the list of names, until verbal consent
to be randomised to either arm was obtained from 50
GPs. This addressed the potential for selection bias inher-
ent in cluster trials [23,24,29], where participation rates
differ between the groups following allocation.
The GPs were stratified by location (metropolitan/rural)
in an attempt to address the association between geo-
graphical location and women's uptake of prenatal diag-
nostic testing [30]. Random allocation was obtained using
a computer generated random list of numbers.
Academic detailing of GPs
Following randomisation, visits to the practices of all GPs
were arranged. Prior to the visits a detailed information
sheet on the ADEPT study and consent form were mailed
to each GP together with a survey. The survey, collected at
the visit, requested information that included a descrip-
tion of their role in prenatal testing and details of their
usual practice including the amount of time they spend
counselling women, the importance they attach to
women of different age groups having adequate informa-
tion and having testing. Professional history and socio-
demographic details were also collected.
Members of the project team (SL & CN) conducted all vis-
its according to an agreed practice visit schedule. The
project was described in detail, as was the role of the GP
and the process involved in enrolling a woman in the
ADEPT study. GPs were provided with the project
resources including a manual and ten information packs
for women.
Enrolling women in the ADEPT study
Each GP was asked to provide information on the ADEPT
study and to offer participation to all pregnant women
meeting the study's selection criteria (see Additional file
3). The risk of selection bias recognised in cluster trials
[31] will be measured by way of an audit (see Additional
file 4) using details collected by the GP on the age, parity
and country of birth of all women meeting the selection
criteria during the recruitment period. Australian GPs are
primarily funded by a fee for service system and receive no
funding (personal or infrastructure) for involvement in
research. GPs have been reimbursed for the time spent
enrolling a woman to the study ($30AUD/woman).
GPs needed to obtain written informed consent from
women wanting to participate in ADEPT as well as the
woman's contact details and estimated date of delivery.
These details were faxed/posted to the project office. The
GP provided each participating women with an informa-
tion resource (decision aid or pamphlet) and the first
questionnaire, as well as written instructions, an informa-
tion sheet and a copy of the consent form she signed.
Inclusion criteria for women
Pregnant women attending a participating GP were eligi-
ble to participate provided they were aged 18 years or
older and were equal to, or less than, 12 weeks gestation.
Exclusion criteria for women
Women were excluded if they were non-English speaking,
were unable to give written informed consent or required
genetic counselling due to a family history of an inherited
condition or recurrent risk for fetal abnormality. Exclu-
sion criteria also included having already undertaken test-
ing for fetal abnormality in this pregnancy, experiencing
vaginal bleeding or currently having a known multiple
pregnancy.
Data collection from women
Women were asked to complete two questionnaires, the
first by 14 weeks gestation and the second at approxi-
mately 24 weeks gestation. The initial questionnaire was
given to the woman by her GP and the second question-
naire was forwarded to her postal address by the project
team. Stamped addressed envelopes have been provided
for the return of both questionnaires.Page 4 of 8
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woman by her GP, an enrolment form detailing the date,
woman's name, contact details and estimated due date
was faxed to the study office. This information was
entered into a database to manage the reminder system
for the questionnaires as well as the mail-out of the sec-
ond questionnaire.
Using a modification of the technique described by Dill-
man [32], a two-stage reminder system is in place to max-
imise the response rate of the questionnaires. Women are
contacted with a reminder letter two weeks after the ques-
tionnaire is due if it has not been received. A phone call
reminder follows in a further two weeks if the question-
naire remains unreturned.
Blinding
Blinding of researchers was not practical in this study,
however a person independent of the study has kept the
master list of all randomised groups and will audit the
integrity of the randomisation prior to analysis.
Participating women were made aware that two methods
of providing information were being trialed but were not
advised of the alternative resource to the one they
received.
Allocation concealment
Concealment of allocation was achieved by obtaining
GP's verbal consent to be randomised prior to the conduct
of the randomisation. The research team members were
not advised of the allocation until consent had been
obtained from all GPs. GPs were unaware of the arm of
the trial to which they had been randomised until the
time of the practice visit.
Data entry quality control
Prior to analysis, a random sample of ten percent of the
data entry will be audited. A person independent of the
study will conduct the sampling and audit. The rate of
accuracy will be reported.
Scales
ADEPT is using validated and psychometrically robust
self-report scales.
The Multi-dimensional Measure of Informed Choice
(MMIC) [11] scale defines an informed choice as one that
is based on relevant knowledge, is consistent with a per-
son's values and is behaviourally implemented. Three
dimensions are incorporated in this measure: knowledge,
attitude and uptake. There are eight knowledge items and
four items on attitudes to screening tests. A record of test
uptake is included in the measure. Dichotomous out-
comes are classified as informed choice or uninformed
choice. The classification of an informed choice is deter-
mined by a score higher than the midpoint of the knowl-
edge scale (>4), higher than the midpoint of the attitude
scale (>12) and having the test. Equally, a choice is classi-
fied as informed when a score is higher than the midpoint
of the knowledge scale (>4), less than the midpoint of the
attitude scale (equal or <12) and not having the test [33].
The Decisional Conflict Scale [15] contains 16 items
divided into three sub-scales: uncertainty about selection
of alternatives; specific factors contributing to uncertainty
and perceived effectiveness of decision-making. Respond-
ents use a five-point Likert scale (1 = strongly agree to 5 =
strongly disagree). The mean scores are reported for the
total scale and each sub-scale. Higher scores indicate
higher decisional conflict.
The Attitudes to the Fetus/Neonate [34] measure consists
of 15 adjectives and respondents use a seven point scale (0
= Not at all to 7 = extremely) to describe their feelings in
relation to being pregnant (nine items) and towards the
fetus (six items). By reversing specific items the mean
scores are calculated for attitudes to pregnancy and the
fetus, with higher scores indicating a more positive atti-
tude.
The Edinburgh Postnatal Depression Scale [35] has been
validated to use prenatally. It contains ten items and
respondents have four options available to indicate the
frequency of the event based on their experience of the
previous week. With the reversing of specific responses,
items are scored (1–4) and women can be classified as
probably clinically depressed (≥ 13) or not (<13).
The short version of the Speilberger State- Trait Anxiety
Inventory (STAI – State) contains six items [36]. Respond-
ents use a four-point Likert scale to indicate how they feel
now (1 = Not at all to 4 = Very much). With the reversing
of specific responses, mean scores are reported with
higher scores indicating greater anxiety.
The Satisfaction with Decision [37] scale contains five
items and respondents use a five point Likert scale (1 =
strongly agree to 5 = strongly disagree). With the reversing
of specific responses, mean scores are calculated with
higher scores indicating greater satisfaction.
Outcomes
The two primary outcomes for the study are informed
choice and decisional conflict. Informed choice will be
measured by the percentage of women in each arm of the
trial identified as making an informed choice using the
MMIC [11]. Decisional conflict will be measured by the
difference in mean scores of the Decisional Conflict Scale
[15] between women in each arm. Both primary out-Page 5 of 8
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tionnaire to reflect women's experience closest to the time
they were making decisions about prenatal testing.
Secondary outcomes include attitudes to the pregnancy/
fetus, depression, anxiety, and acceptability of the written
information by women and GPs. These outcomes will be
measured using data from the first questionnaire.
Women's satisfaction with their decision [37] will be
assessed using data from the second questionnaire.
Changes in primary and secondary outcomes will be
measured by comparing responses from the second ques-
tionnaire with the first. Attitudes to the pregnancy/fetus
will be assessed using the scale developed by Reading et al
(1984) [34] by measuring the difference in mean scores
between women in both arms of the trial. Depression will
be measured using the difference in percentages of
women in both arms of the trial identified as being prob-
ably clinically depressed on the EPDS [35]. Anxiety will be
measured as the difference in the mean Anxiety STAI-State
(short version) score of women in both arms of the trial
[36]. The acceptability of the decision aid/pamphlet to
women and GPs will be measured by comparing the dif-
ference in proportions of descriptive items between
women in both arms of the trial and comparing content
analysis of open-ended comments.
Satisfaction with decision making will be measured using
the difference in mean Satisfaction with Decision Scale
[37] scores between women in both arms of the trial.
Discussion
Standard guidelines for statistical reporting of clinical tri-
als will be followed [38] with additional information
relating to the cluster design [31,39,40]. Baseline charac-
teristics of women including age group, marital status,
educational level, income source, country of birth, reli-
gion will be compared between the intervention and con-
trol arms of the trial. In addition, obstetric history,
previous experience with prenatal screening tests, percep-
tion of risk of Down syndrome and personal experience
with individuals who have disabilities such as Down syn-
drome will be compared between arms of the trial. GPs
will be compared between arms in relation to age, gender,
country of graduation, years of general practice, postgrad-
uate education and personal and professional experience
with individuals who have disabilities like Down syn-
drome. In addition we will compare GPs in both arms of
the trial on the basis of the average time spent informing
women of prenatal tests and the importance they attach
both to providing this information and to women having
prenatal testing.
Differences in the primary outcomes will be analysed
using 'intention-to-treat' principles. The primary outcome
of informed choice is binary and analysis will use logistic
regression to evaluate the difference in proportions
between the two arms of the trial. Linear regression will be
used for the other primary outcome, decisional conflict, to
evaluate the difference in mean scores between the two
arms of the trial. Adjustment will be made for the stratifi-
cation variable, geographical location (metropolitan/
rural), and the following major potential confounding
factors: maternal age, education level, gravidity, socioeco-
nomic status and country of birth. Confidence intervals
and P values will be adjusted for the effect of clustering
and loss to follow-up within clusters will be reported.
Secondary outcomes will use appropriate regression tech-
niques and covariate adjustments.
Competing interests
The author(s) declare they have no completing interests.
Authors' contributions
JH generated the original research question and together
with JG, RB, SM, BM & JC developed the project and
obtained funding. This group together with SL & CN
refined the protocol. CN & SL developed the materials
used in the trial with input from other authors. CN wrote
the first draft of this paper and all other authors contrib-
uted to subsequent drafts and approved the final version.
Additional material
Additional file 1
Woman's information statement and consent form. This file contains the 
information provided to women and the consent form women signed for 
the ADEPT study.




Letter of invitation sent to General Practitioners. This file contains the 
content of the letter of invitation to participate in the ADEPT study sent 
to all GPs in the targeted geographical areas




Flow-chart of enrolling a woman in the ADEPT study. This file contains 
details of the selection criteria and a flow diagram of the process of enrol-
ment.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2458-6-96-S3.doc]
Additional file 4Page 6 of 8
(page number not for citation purposes)
BMC Public Health 2006, 6:96 http://www.biomedcentral.com/1471-2458/6/96Acknowledgements
This project is funded by the National Health and Medical Research Council 
(Project Grant 237124). Bettina Meiser and Jane Halliday are both sup-
ported by Career Development Awards (ID 350989 and 216741 respec-
tively).
The authors thank all the women and GPs who contributed to the devel-
opment of the decision aid by participating in the focus groups and to those 
who are participating in the trial.
We gratefully acknowledge the assistance and advice of Dr Peter Rose in 
reviewing the decision aid.
References
1. Johnson J, Summers A: Prenatal Genetic Screening for Down
Syndrome and Open Neural Tube Defects using Maternal
Serum Marker Screening.  SOGC Clinical Practice Guidelines 1999.
2. Royal Australian and New Zealand College of Obstetricians and
Human Genetics Society of Australasia: Joint HGSA/RANZCOG
recommended ' Best Practice' Guidelines on antenatal
screening for Down syndrome and other fetal aneuploidy.
2004.
3. Royal College of Obstetricians and Gynaecologists: Antenatal
screening for Down syndrome.  London, Royal College of Obste-
tricians and Gynaecologists, available online: www.rcog.org.uk/
resources/Public/pdf/Down_syndrome_Screening.pdf; 2003. 
4. Jaques AM, Halliday JL, Bell RJ: Do women know that prenatal
testing detects fetuses with Down syndrome?  Journal of Obstet-
rics and Gynaecology 2004, 24:647-651.
5. De Vigan C, Vodovar V, Goujard J, Garel M, Vayssiere C, Goffinet F:
Mothers' knowledge of screening for trisomy 21 in 1999: a
survey in Paris maternity units.  Eur J Obstet Gynecol Reprod Biol
2002, 104:14-20.
6. Mulvey S, Wallace E: Levels of knowledge of Down syndrome
and Down syndrome testing in Australian women.  Aust NZ J
Obstet Gynaecol 2001, 41:167-169.
7. Rostant K, Steed L, O'Leary P: Survey of the knowledge, atti-
tudes and experiences of Western Australian women in rela-
tion to prenatal screening and diagnostic procedures.  Aust N
Z J Obstet Gynaecol 2003, 43:134-138.
8. Metcalfe S, Seipolt M, Aitken M, Flouris A: Educating general prac-
titioners about prenatal testing: approaches and challenges.
Prenat Diagn 2005, 25:592-601.
9. Tyzack K, Wallace E: Down syndrome screening: what do
health professionals know?  Australian and New Zealand Journal of
Obstetrics and Gynaecology 2003, 43:217-221.
10. Rostant K, Steed L, O'Leary P: Prenatal screening and diagnosis:
A survey of health care providers' knowledge and attitudes.
Australian and New Zealand Journal of Obstetrics and Gynaecology 2003,
43:307-311.
11. Marteau TM, Dormandy E, Michie S: A measure of informed
choice.  Health Expectations 2001, 4:99-108.
12. O'Connor AM, Stacey D, Rovner D, Holmes-Rovner M, Tetroe J,
Llewellyn-Thomas H, Entwistle V, Rostom A, Fiset V, Barry M, Jones
J: Decision aids for people facing health treatment or screen-
ing decisions.  Cochrane Database of Systematic Reviews 2003.
13. O'Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V, Llewellyn-
Thomas H, Holmes-Rovner M, Barry M, Jones J: Decision aids for
patients facing health treatment or screening decisions: sys-
tematic review.  British Medical Journal 1999, 319:731-734.
14. Hunter AGW, Chappelli M, Humphreys L, Allanson JE, Chiu TT,
Peeters C, Moher D, Zimak A: A randomized trial comparing
alternative approaches to prenatal diagnosis counseling in
advanced maternal age patients.  Clinical Genetics 2005,
67:303-313.
15. O'Connor AM: Validation of a decisional conflict scale.  Medical
Decision Making 1995, 15:25-30.
16. O'Connor AM, Tugwell P, Wells GA, Elmsie T, Jolly E, Bunn H, Gra-
ham I, Drake E: The Ottawa decision support framework
(DSF) guiding the development of decision aids for patients
and practitioners considering health care interventions.
Ottawa, University of Ottawa School of Nursing; 1998. 
17. Snijders RJ, Sebire NJ, Nicolaides KH: Maternal age and gesta-
tional age-specific risk for chromosomal defects.  Fetal Diagno-
sis and Therapy 1995, 10:356-367.
18. Reynolds TM: Screening by test combination: a statistical
overview.  In Screening for Down's Syndrome Edited by: Grudzinskas
JG. Cambridge, Cambridge University Press; 1994. 
19. World Medical Association: Ethical Principles for Medical
Research Involving Humans.  Helsinki, World Medical Associa-
tion available online http://www.wma.net/e/policy/b3.htm.; 1964. 
20. Riley M, King J: Births in Victoria 2001-2002.  2003 [http://
www.health.vic.gov.au/perinatal/]. Melbourne, Perinatal Data Collec-
tion Unit, Public Health, Victorian Government Department of
Human Services
21. Muggli E, Halliday J: Prenatal diagnostic testing and Down syn-
drome in Victoria 1992-2002.  Australian and New Zealand Journal
of Public Health 2004, 28:465-470.
22. Muggli E, Halliday J: Prenatal Diagnostic Testing in Victoria in
2004.  Melbourne, Murdoch Childrens Research Institute and Victo-
rian Perinatal Data Collection Unit, Department of Human Services;
2005. 
23. Torgerson DJ: Contamination in trials: is cluster randomisa-
tion the answer?  BMJ 2001, 322:355-357.
24. Donner A, Klar N: Pitfalls of and controversies in cluster rand-
omization trials.  American Journal of Public Health 2004,
94:416-422.
25. Knox SA, Chondros P: Observed intra-cluster correlation coef-
ficients in a cluster survey ample of patient encounters in
general practice in Australia.  BMC Medical Research Methodology
2004, 4:.
26. Ellish NJ, Saboda K, O'Connor J, Nasca PC, Stanek EJ, Boyle C: A
prospective study of early pregnancy loss.  Human Reproduction
1996, 11:406-412.
27. Graham W, P. S, Fitzmaurice A, Smith N, Hamilton N: Randomised
controlled trial comparing effectiveness of touch screen sys-
tem with leaflet for providing women with information on
prenatal tests.  British Medical Journal 2000, 320:155-160.
28. Riley M, Halliday J: Birth Defects in Victoria 2001-2002.  Mel-
bourne, Perinatal Data Collection Unit, Public Health, Victorian Gov-
ernment Department of Human Services, available online: http://
www.dhs.vic.gov.au/phd/perinatal/pubs.htm; 2004. 
29. Hung S, Puffer S, Torgerson DJ, Watson J: Methodological bias in
cluster randomised trials.  BMC Medical Research Methodology
2005, 5:1-8.
30. Halliday J, Lumley J, Watson L: Comparison of women who do
and do not have amniocentesis or chorionic villus sampling.
The Lancet 1995, 345:704-709.
31. Puffer S, Torgerson DJ, Watson J: Evidence for risk of bias in clus-
ter randomised trials: review of recent trials published in
three general medical journals.  BMJ 2003, 327:1-5.
32. Dillman DA: Mail and Internet Surveys:The Tailored Design
Method.  Second edition. New York, John Wiley & Sons; 2000. 
33. Michie S, Dormandy E, Marteau TM: Informed choice: under-
standing knowledge in the context of screening uptake.
Patient Education & Counseling 2003, 50:247-253.
34. Reading AE, Cox DN, Sledmere CM, Campbell S: Psychological
changes over the course of pregnancy: a study of attitudes
toward the fetus/neonate.  Health Psychology 1984, 3:221-221.
35. Cox JL, Chapman G, Murray D, Jones P: Validation of the Edin-
burgh Postnatal Depression Scale (EPDS) in non-postnatal
women.  J Affect Disord 1996, 39:185-189.
36. Marteau TM, Bekker H: The development of a six-item short-
form of the state scale of the Spielberger State-Trait Anxi-
ety Inventory (STAI).  British Journal of Clinical Psychology 1992,
31:301-306.
37. Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert
ML, Padonu G, Talarczyk G: Patient satisfaction with health care
Audit of recruitment profile. This file contains the audit form used by GPs 
to collect demographic data on all women eligible to participate in the 
trial.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2458-6-96-S4.doc]Page 7 of 8
(page number not for citation purposes)
BMC Public Health 2006, 6:96 http://www.biomedcentral.com/1471-2458/6/96Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
decision: the satisfaction with decision scale.  Medical Decision
Making 1996, 16:58-64.
38. Moher D, Schulz KF, Altman D: The CONSORT statement:
Revised Recommendations for Improving the Quality of
Reports of Parallel-Group Randomized Trials.  JAMA 2001,
285:1987-1991.
39. Donner A, Piaggio G, Villar J: Statistical methods for the meta-
analysis of cluster randomization trials.  Statistical Methods in
Medical Research 2001, 10:325-338.
40. Campbell M, Elbourne D, Altman D: CONSORT statement:
extension to cluster randomised trials.  BMJ 2004, 328:702-708.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2458/6/96/prepubPage 8 of 8
(page number not for citation purposes)
